Jim Simons Immunocore Holdings PLC Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 564,800 shares of IMCR stock, worth $27.7 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

564,800

Previous 345,100 63.66%

Holding current value

$27.7 Million

Previous $23.6 Million 55.71%

% of portfolio

0.06%

Previous 0.04%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$60.14 - $75.36 $13.2 Million - $16.6 Million	219,700 Added 63.66%	564,800 $36.7 Million
Q4 2023 Feb 13, 2024	SELL	$42.85 - $69.5 $4.76 Million - $7.73 Million	-111,200 Reduced 24.37%	345,100 $23.6 Million
Q3 2023 Nov 14, 2023	BUY	$49.5 - $66.6 $445,500 - $599,400	9,000 Added 2.01%	456,300 $23.7 Million
Q2 2023 Aug 11, 2023	BUY	$48.54 - $61.64 $131,058 - $166,428	2,700 Added 0.61%	447,300 $26.8 Million
Q1 2023 May 12, 2023	BUY	$46.12 - $65.71 $6.43 Million - $9.17 Million	139,500 Added 45.72%	444,600 $22 Million

Q4 2022 Feb 13, 2023	BUY	$45.51 - $65.08 $9.57 Million - $13.7 Million	210,300 Added 221.84%	305,100 $17.4 Million
Q3 2022 Nov 14, 2022	BUY	$37.34 - $57.44 $1.64 Million - $2.52 Million	43,900 Added 86.25%	94,800 $4.45 Million
Q2 2022 Aug 12, 2022	BUY	$25.46 - $37.72 $1.11 Million - $1.64 Million	43,600 Added 597.26%	50,900 $1.9 Million
Q1 2022 May 13, 2022	BUY	$18.94 - $34.29 $138,262 - $250,317	7,300 New	7,300 $218,000

Others Institutions Holding IMCR

# of Institutions

163

Shares Held

37.8M

Call Options Held

540K

Put Options Held

97.3K

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $2.15B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account